IMDX Insight Molecular Diagnostics Inc.
USHealthcareAs of 2026-07-10 16:00
Why IMDX matters now
Insight Molecular Diagnostics Inc. (IMDX) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.08 with +4.74% on the session and $136.4M in market capitalization; recent performance reads 1-month -2.16% and YTD -27.47%.
The latest financial table shown here is Q1 2026, with revenue of $32.0K, net income of $-4.3M, and EPS of $-0.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -18.8%.
The latest indexable market news headline is "IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $12.00; recent insider activity includes Arno Andrew filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-17.56
P/S
74.92
EV/EBITDA
-2.66
DCF Value
$-2.67
FCF Yield
-18.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
19.5%
Operating Margin
-2112.4%
Net Margin
-2454.6%
ROE
380.8%
ROA
-118.3%
ROIC
-136.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $32.0K | $-4.3M | $-0.12 |
| Q4 2025 | $1.1M | $-23.0M | $-0.75 |
| FY 2025 | $4.1M | $-50.2M | $-1.65 |
| Q3 2025 | $260.0K | $-10.9M | $-0.34 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
1.79
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.